Edwards Lifesciences Corporation $EW Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 23.5% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 16,827,967 shares of the medical research company’s stock after selling 5,183,134 shares during the quarter. Wellington Management Group LLP’s holdings in Edwards Lifesciences were worth $1,522,258,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $266,000. NewEdge Advisors LLC grew its holdings in shares of Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares during the period. Sei Investments Co. increased its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC increased its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Annette Bruls sold 2,644 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,501 shares of company stock worth $408,213 over the last three months. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 0.3%

Shares of EW opened at $90.19 on Friday. The firm has a market cap of $51.93 billion, a P/E ratio of 51.83, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company’s 50-day moving average price is $89.54 and its 200 day moving average price is $85.03. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on EW. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Citigroup raised their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Evercore reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.